Class patent landscape
Retinoid
Cross-drug patent estate across 10 approved drugs in the retinoid class. Loss-of-exclusivity timeline, sponsor concentration, and per-drug links to full patent landscapes.
Approved drugs
10
with patent data
OB patents
57
across the class
Patent families
26
665 docs · 36 countries
Earliest US LOE
Jul 17, 2027
first drug off patent
Latest US LOE
May 22, 2041
last drug off patent
Loss-of-exclusivity waterfall
Drugs in the retinoid class sorted by US Orange Book expiry — earliest LOE first. Each row links to the drug's full patent landscape.
| Drug | Sponsor | OB patents | Families | Intl docs | Latest US expiry | |
|---|---|---|---|---|---|---|
| EPIDUO adapalene | GALDERMA LABS LP | 3 | 2 | 55 | Jul 17, 2027 +1y | View → |
| DIFFERIN adapalene | GALDERMA LABS LP | 3 | 1 | 16 | May 30, 2028 +2y | View → |
| FABIOR tazarotene | MAYNE PHARMA | 3 | 1 | 38 | Feb 23, 2030 +4y | View → |
| AKLIEF trifarotene | GALDERMA LABS LP | 3 | 3 | 43 | May 29, 2033 +7y | View → |
| DUOBRII halobetasol propionate | BAUSCH | 10 | 3 | 90 | Jun 5, 2036 +10y | View → |
| SOHONOS palovarotene | IPSEN | 9 | 2 | 101 | Jun 7, 2037 +11y | View → |
| ARAZLO tazarotene | BAUSCH | 3 | 2 | 45 | May 10, 2038 +12y | View → |
| ALTRENO tretinoin | DOW PHARM | 2 | 1 | 15 | Aug 21, 2038 +12y | View → |
| CABTREO adapalene | BAUSCH | 8 | 2 | 74 | Dec 27, 2040 +14y | View → |
| TWYNEO benzoyl peroxide | MAYNE PHARMA | 13 | 10 | 188 | May 22, 2041 +15y | View → |
Sponsor concentration
Which companies anchor the IP across this class.
Pro Sponsor concentration — Which sponsors anchor the IP across the class
See what Pro includes ↓ Methodology & data sources
- Drugs in class: aggregated from
drug.pharmClassEpcfield. Drugs without EPC tags are not included here (data gap, not coverage limitation). - Patent data: per-drug patent thickets from FDA Orange Book / Purple Book + BigQuery family expansion. See individual drug patent pages for source detail.
- LOE waterfall: sorted by
latestPatentExpiryfrom Orange Book. Reflects US patent term adjustments (PTA) but not exclusivity overlays (ODE, NPP, PED). - Class-level analysis: sums across per-drug thickets. Same patent family may appear in multiple drugs (e.g., Jakafi + Opzelura share composition family) — counted once per family per drug for OB totals.
Intelligence, not legal advice. Class-level summary reflects what's listed publicly. Generic launch dynamics depend on per-drug NCE/ODE/PED overlays, ANDA Para IV outcomes, and BPCIA settlements not captured here.
TheraRadar Pro — patent intelligence
Free covers what's publicly listed: Orange Book patents, basic stats, composition expiry. Pro adds the deeper view: LLM-driven estate analysis, full international family thicket, and (coming soon) alerts + exports.
Always free
- • Orange Book patent table (every patent, family, use code, expiry)
- • Stat strip — OB count, families, global doc footprint, multiplier
- • Composition family priority + nominal global expiry
- • International vs US expiry comparison
- • Coverage status + methodology
- • LOE waterfall across all approved drugs in the class
PRO
What Pro adds today
- Estate analysis (sections 2-5) — Composition anchor, lifecycle layers, international vs US, strategic outlook
- Full patent families table — Country lists, doc counts, priority dates per family
- Sponsor concentration — Who owns the IP across the class
- International nominal expiries — Priority + 20 years per family with global vs US gap
$99/year. Cancel anytime. Single sign-on via Google.
Class patent data updated: Jun 17, 2026